Literature DB >> 27427153

Targeting WEE1 Kinase in Cancer.

Christopher J Matheson1, Donald S Backos1, Philip Reigan2.   

Abstract

WEE1 kinase plays a crucial role in the G2-M cell-cycle checkpoint arrest for DNA repair before mitotic entry. Normal cells repair damaged DNA during G1 arrest; however, cancer cells often have a deficient G1-S checkpoint and depend on a functional G2-M checkpoint for DNA repair. WEE1 is expressed at high levels in various cancer types including breast cancers, leukemia, melanoma, and adult and pediatric brain tumors. Many of these cancers are treated with DNA-damaging agents; therefore, targeting WEE1 for inhibition and compromising the G2-M checkpoint presents an opportunity to potentiate therapy. In this review we summarize the current WEE1 inhibitors, the potential for further inhibitor development, and the challenges in the clinic for the WEE1 inhibitor strategy.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DNA-damaging agents; Wee1; combination therapy; inhibitor; kinase

Mesh:

Substances:

Year:  2016        PMID: 27427153     DOI: 10.1016/j.tips.2016.06.006

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  118 in total

1.  HPLC-UV method for simultaneous determination of MK-1775 and AZD-7762 in both acetonitrile-aqueous solution and mouse plasma.

Authors:  Kareem Ebeid; Giang N Ho; Aliasger K Salem
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-12-30       Impact factor: 3.205

Review 2.  Post-translational modifications of Hsp90 and translating the chaperone code.

Authors:  Sarah J Backe; Rebecca A Sager; Mark R Woodford; Alan M Makedon; Mehdi Mollapour
Journal:  J Biol Chem       Date:  2020-06-11       Impact factor: 5.157

Review 3.  Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy.

Authors:  Christopher C Mills; E A Kolb; Valerie B Sampson
Journal:  Cancer Res       Date:  2018-01-08       Impact factor: 12.701

4.  Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy.

Authors:  Christopher J Matheson; Kimberly A Casalvieri; Donald S Backos; Philip Reigan
Journal:  ChemMedChem       Date:  2018-07-11       Impact factor: 3.466

Review 5.  Dying to protect: cell death and the control of T-cell homeostasis.

Authors:  Kun-Po Li; Sharmila Shanmuganad; Kaitlin Carroll; Jonathan D Katz; Michael B Jordan; David A Hildeman
Journal:  Immunol Rev       Date:  2017-05       Impact factor: 12.988

6.  Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.

Authors:  Tamara B Garcia; Susan P Fosmire; Christopher C Porter
Journal:  Leuk Res       Date:  2017-11-11       Impact factor: 3.156

7.  Hematopoietic PBX-interacting protein is a substrate and an inhibitor of the APC/C-Cdc20 complex and regulates mitosis by stabilizing cyclin B1.

Authors:  Saratchandra Singh Khumukcham; Venkata Subramanyam Kumar Samanthapudi; Vasudevarao Penugurti; Anita Kumari; P S Kesavan; Loka Reddy Velatooru; Siva Reddy Kotla; Aprotim Mazumder; Bramanandam Manavathi
Journal:  J Biol Chem       Date:  2019-05-17       Impact factor: 5.157

Review 8.  Synthetic Lethality through the Lens of Medicinal Chemistry.

Authors:  Samuel H Myers; Jose Antonio Ortega; Andrea Cavalli
Journal:  J Med Chem       Date:  2020-11-02       Impact factor: 7.446

9.  Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.

Authors:  Weizhen Liu; Xiangyu Zeng; Yuping Yin; Chengguo Li; Wenchang Yang; Wenze Wan; Liang Shi; Guobin Wang; Kaixiong Tao; Peng Zhang
Journal:  Gastric Cancer       Date:  2019-06-13       Impact factor: 7.370

Review 10.  Unravelling the biology of SCLC: implications for therapy.

Authors:  Joshua K Sabari; Benjamin H Lok; James H Laird; John T Poirier; Charles M Rudin
Journal:  Nat Rev Clin Oncol       Date:  2017-05-23       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.